Activation-Induced Cytidine Deaminase Expression in Human B Cell Precursors Is Essential for Central B Cell Tolerance  by Cantaert, Tineke et al.
ArticleActivation-Induced Cytidine Deaminase Expression
in Human B Cell Precursors Is Essential for Central B
Cell ToleranceHighlightsd AID is co-expressed with RAG2 in some bone marrow
immature B cells
d Most AID+ immature B cells also co-expressed BCL6 like
germinal center B cells
d AID+ immature B cells lack anti-apoptotic MCL-1 and are
deleted by apoptosis
d B cell intrinsic AID expression mediates central B cell
toleranceCantaert et al., 2015, Immunity 43, 884–895
November 17, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.immuni.2015.10.002Authors
Tineke Cantaert, Jean-Nicolas
Schickel, Jason M. Bannock, ...,
Shigeaki Nonoyama, Anne Durandy,
Eric Meffre
Correspondence
eric.meffre@yale.edu
In Brief
AID is the enzyme-mediating class-
switch recombination and somatic
hypermutation. Meffre and colleagues
demonstrate that AID inhibition in
developing B cells resulted in a failure to
remove autoreactive clones. Hence, B
cell-intrinsic AID expression mediates
central B cell tolerance potentially
through RAG-coupled genotoxic activity
in self-reactive immature B cells.
Immunity
ArticleActivation-Induced Cytidine Deaminase
Expression in Human B Cell Precursors
Is Essential for Central B Cell Tolerance
Tineke Cantaert,1,10 Jean-Nicolas Schickel,1,10 Jason M. Bannock,1 Yen-Shing Ng,1 Christopher Massad,1 Tyler Oe,1
Renee Wu,1 Aubert Lavoie,2 Jolan E. Walter,3,4 Luigi D. Notarangelo,4 Waleed Al-Herz,5 Sara Sebnem Kilic,6
Hans D. Ochs,7 Shigeaki Nonoyama,8 Anne Durandy,9 and Eric Meffre1,*
1Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA
2Division of Immunology/Allergy, Centre Hospitalier de l’Universite´ de Que´bec, Que´bec City, G1V 4G2, Canada
3Pediatric Allergy & Immunology and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard
Medical School, Boston, MA 02114, USA
4Division of Immunology, Boston Children’s Hospital, Boston, MA 02115, USA
5Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, 13110, Kuwait
6Uludag University Medical Faculty, Department of Pediatrics, Gorukle-Bursa, 16285, Turkey
7Seattle Children’s Research Institute and Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
8Department of Pediatrics, National Defense Medical College, Namiki, Tokorozawa, Saitama, 359-8513, Japan
9INSERM UMR 1163, Paris 75015, France
10Co-first author
*Correspondence: eric.meffre@yale.edu
http://dx.doi.org/10.1016/j.immuni.2015.10.002SUMMARY
Activation-induced cytidine deaminase (AID), the en-
zyme-mediating class-switch recombination (CSR)
and somatic hypermutation (SHM) of immunoglobulin
genes, is essential for the removal of developing au-
toreactive B cells. How AID mediates central B cell
tolerance remains unknown. We report that AID en-
zymes were produced in a discrete population of
immature B cells that expressed recombination-acti-
vating gene 2 (RAG2), suggesting that they undergo
secondary recombination to edit autoreactive anti-
bodies. However, most AID+ immature B cells lacked
anti-apoptoticMCL-1 andwere deleted by apoptosis.
AID inhibition using lentiviral-encoded short hairpin
(sh)RNA in B cells developing in humanized mice re-
sulted in a failure to remove autoreactive clones.
Hence, B cell intrinsic AID expression mediates cen-
tral B cell tolerance potentially through its RAG-
coupled genotoxic activity in self-reactive immature
B cells.
INTRODUCTION
The expression of activation-induced cytidine deaminase (AID),
the enzyme-mediating class-switch recombination (CSR) and
somatic hypermutation (SHM) (Muramatsu et al., 2000; Revy
et al., 2000), is required for the establishment of central B cell
tolerance (Kuraoka et al., 2011; Meyers et al., 2011). Indeed,
AID-deficient patients show an increased frequency of autor-
eactive clones exiting their bone marrow (BM) (Meyers et al.,
2011). In addition, Aicda/ mice also display central B cell
tolerance defects, suggesting a conserved role for AID during884 Immunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc.early B cell development in mice and humans (Kuraoka et al.,
2011).
The analysis of patients with primary immunodeficiency due to
diverse gene mutations reveals that central B cell tolerance re-
quires intact B cell receptors (BCR) and possibly Toll-like recep-
tors (TLR) signaling pathways, perhaps triggered by binding to
self-antigens at the immature B cell stage (Isnardi et al., 2008;
Menard et al., 2014; Ng et al., 2004; Romberg et al., 2013; Sauer
et al., 2012). These findings, together with the identification of
AID transcripts in B cell precursors in both mice and humans,
support the idea that AID expression in immature B cells is rele-
vant to tolerance induction (Han et al., 2007; Kuraoka et al., 2009;
Mao et al., 2004; Meyers et al., 2011; Ueda et al., 2007; Umiker
et al., 2014). However, it remains to be determined whether the
AID enzyme is in fact expressed in some B cell precursors or
whether central B cell tolerance defects in AID-deficient patients
or mice might be related to their susceptibility to infections in the
absence of isotype switched, affinity-matured antibodies.
Here, we report that AID proteins are expressed during early B
cell development in both human fetal liver and adult bone
marrow. AID expression was found restricted to early immature
B cells that co-express recombination-activating gene 2 (Rag2)
and undergo apoptosis. Furthermore, we show that AID inhibi-
tion in B cells developing in humanized mice impaired the coun-
terselection of autoreactive clones, revealing B cell intrinsic AID
requirement to ensure central B cell tolerance. However, autor-
eactive B cell deletion through AID and RAG-coupled genotoxic
activity occurred at the potential expense of inducing chromo-
somal translocations that might promote lymphomagenesis.RESULTS
AID Gene Dosage Regulates Central B Cell Tolerance
To further assess AID requirement for the central removal of
autoreactive clones, we analyzed the reactivity of antibodies
expressed by single CD19+CD27CD10+IgMhiCD21lo transi-
tional B cells that recently emigrated from the bone marrow of
additional AID-deficient patients carrying autosomal recessive
(AR) mutations and asymptomatic heterozygote relatives, as
well as rare patients with autosomal dominant (AD) AICDA mu-
tations or Uracil N-glycosylase (UNG)-deficiency (Tables S1, S2,
and S3). AD-AICDA mutations result in the deletion of the last
amino acids of AID required for CSR activity; C-terminal trun-
cated AID products also lack the nuclear export signal and
therefore remain in the nucleus where they exert a dominant-
negative role on CSR (Imai et al., 2005; Ito et al., 2004; Zahn
et al., 2014). UNG acts downstream of AID and removes AID-
induced uracil residues from DNA to create abasic sites (Di
Noia and Neuberger, 2007). UNG-deficiency greatly affects
CSR but leaves the frequency of SHM intact, albeit with an
altered mutation spectrum (Imai et al., 2003). In agreement
with these reports, patients with AD-AICDA mutations or
UNG-deficiency are similar to AID-deficient patients in that
they are virtually devoid of isotype-switched B cells, whereas
AICDA+/ asymptomatic relatives display normal isotype-
switched memory B cell frequencies (Figure S1) (Imai et al.,
2003; Imai et al., 2005).
We found that patients with AD-AICDA mutations differed
from AID-deficient patients in that they displayed normal
frequencies of polyreactive, HEp-2 reactive, and anti-nuclear
clones, revealing a functional central B cell tolerance in
these individuals in which AID enzymatic activity is preserved
(Figure 1 and Figure S2) (Imai et al., 2005; Zahn et al., 2014).
Moreover, UNG-deficient patients also showed low propor-
tions of autoreactive new emigrant B cells similar to those in
healthy donors (Figure 1 and Figure S2). Hence, impaired
CSR, absence of isotype-switched B cells, or recurrent infec-
tious episodes characteristic of these patients do not impact
the establishment of central B cell tolerance. In contrast,
asymptomatic subjects who carried a heterozygous AR-AICDA
mutation showed significantly elevated frequencies of poly-
reactive and HEp-2 reactive new emigrant B cells, which
averaged 21.3% ± 5.6% and 43.0% ± 3.1%, respectively,
compared to 7.3% ± 2.4% and 34.9% ± 6.1% in healthy
donor counterparts, thereby revealing that these individuals
display central B cell tolerance defects that resembled those
in AID-deficient patients (Figures 1A–1C and Figure S2). These
frequencies were lower than those in AID-deficient patients
carrying two recessive mutated AICDA alleles (Figures 1A–
1C), demonstrating an AICDA gene-dosage-dependent regula-
tion of central B cell tolerance.
Proper AID Enzymatic Activity Is Required for Central B
Cell Tolerance
The impact of heterozygote AR-AICDA mutations on the
removal of developing autoreactive B cells suggested that
AICDA haploinsufficiency might be responsible for central B
cell tolerance defects in asymptomatic AICDA+/ subjects. In
agreement with this hypothesis, B cells from Aicda+/ mice
display decreased AID expression upon activation or immuniza-
tion, resulting in reduced SHM and CSR activity (McBride et al.,
2008; Takizawa et al., 2008).We therefore assessed AID expres-
sion in EBV cell lines derived from six AICDA+/ individuals and
five AID-deficient patients and compared it to that in EBV linesIfrom healthy donors (Figure 2). Quantitative PCR and protein
expression using western blots revealed that both AICDA+/
and AID-deficient EBV lines displayed significantly decreased
AID expression compared to control EBV lines (Figures 2A–
2C) (Imai et al., 2005). We also analyzed AID expression by
histochemistry in primary B cells isolated fromAICDA+/ individ-
uals and AID-deficient patients activated for 5 days with cyto-
kines that induces AID expression in vitro. The reactivity of
both rat and mouse anti-human AID monoclonal antibodies
was validated by staining various types of cells deposited on
slides by cytospin; AID expression was identified in human
CXCR4+ germinal center (GC) B cells but not in peripheral
CD3+ T cells and naive B cells as previously reported (Figure 2D)
(Muramatsu et al., 2000; Revy et al., 2000; Victora et al., 2012).
The specificity of these monoclonal antibodies was demon-
strated by the lack of AID detection in AID-deficient activated
B cells, whereas many activated B cells from healthy donors ex-
pressed AID (Figure 2E and data not shown). Similarly to EBV
lines, AID expression in activated primary B cells from AICDA+/
subjects was found severely decreased in all tested individuals
(Figure 2E). Hence, both B cells from AICDA+/ asymptomatic
individuals and AID-deficient patients fail to properly express
AID, suggesting that AICDA-haploinsufficiency or AID-defi-
ciency might be responsible for the defective central removal
of developing autoreactive B cells.
AID Proteins Are Detected in a Discrete Population of
Immature B Cells
Previous reports identified low amounts of AID transcripts in B
cell precursors but it was unclear how this might support a
function for AID during early B cell development (Han et al.,
2007; Kuraoka et al., 2009; Mao et al., 2004; Meyers et al.,
2011; Ueda et al., 2007). Since central B cell tolerance is regu-
lated primarily by B cell-intrinsic pathways (Meffre, 2011), we
investigated AID expression in human developing B cells. We
first analyzed AID protein expression in situ by immunochem-
istry by assessing AID expression in B cells developing in the
marrow using fetal ribs from 105–115 day old fetuses. We
identified some rare AID+ cells that co-expressed immuno-
globulin M (IgM) heavy chains in fetal ribs, whereas AID
expression was detected in many GC B cells from tonsil tis-
sues (Figure 3A). Because primary lymphoid organs give rise
to many hematopoietic lineages other than B cells, we isolated
CD19+ B cell precursors from human fetal liver and adult
marrow to enrich for cells that may express AID for further
investigation of AID expression in combination with other mol-
ecules produced at different stages of B cell development. We
found that AID+ cells represent 0.9% ± 0.4% of CD19+ B cell
precursors (data not shown). This very low frequency of
CD19+ cells expressing AID proteins in fetal liver or adult BM
might account for their global low AID transcription amount
amplified by quantitative PCRs compared to CXCR4+ GC cells,
most of which express AID, whereas AID transcripts were not
amplified from peripheral CD19+ B and CD4+ T cells (Figure 3B)
(Han et al., 2007; Kuraoka et al., 2009; Mao et al., 2004;
Ueda et al., 2007). If fetal BM or fetal liver B cells express
AID at an equal amount to GC B cells and using spike-in
experiments in which CXCR4+ GC B cells were diluted in
different proportions in AID peripheral B cells, we estimatedmmunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc. 885
Figure 1. AID Gene Dosage Dependent Regulation of Central B Cell Tolerance
(A) Antibodies from new emigrant B cells from healthy donors (HD, n = 12), AID-deficient (AID-def.) patients (n = 6), asymptomatic healthy heterozygotes
(AICDA+/, n = 5), patients with autosomal dominant (AD)AICDAmutation (n = 4), and UNG-deficient (UNG-def.) patients (n = 2) were tested by ELISA for reactivity
against double-stranded DNA (dsDNA), insulin and lipopolysaccharide (LPS). Antibodies were considered polyreactive when they recognized all three analyzed
antigens. Dotted lines show ED38-positive control. Horizontal lines show cut-off OD405 for positive reactivity. For each individual, the frequency of autoreactive
(filled area) and non autoreactive (open area) clones is summarized in pie charts, with the total number of clones tested indicated in the centers. The frequencies of
polyreactive (B), HEp-2 reactive (C), and anti-nuclear (D) new emigrant B cells is summarized. Lines show the mean and dashed line indicates the mean value for
the healthy donors (HD).
(E) Autoreactive antibodies from AID-def. and asymptomatic healthy AICDA+/ heterozygotes new emigrant B cells show various patterns of HEp-2 staining.
Original magnification 40X, scale bar represents 10 mm. Please see Figure S2.that 0.4%–0.55% of B cells in fetal BM or fetal liver would be
expressing AID, a frequency similar to what was determined by
immunofluorescence (Figures 3B and 3C).
We then analyzed the stage of B cell development at which
AID was expressed. We found that AID expressing fetal liver
and adult BM CD19+ cells co-expressed functional IgM heavy
chain products, thereby revealing that AID was not detected in
IgM early B cell precursors but restricted to pre-B or immature
B cell stages (Figures 3D and 3E) (Meffre et al., 2000). We
excluded AID expression at the pre-B cell stage because AID886 Immunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc.and Vpre-B, one of the two proteins encoding the surrogate light
chain expressed at the early pre-B cell stage, were not found in
the same cells (Burrows et al., 2002; Ma˚rtensson et al., 2002).
The identification of kappa or lambda light chains with AID
showed that AID expression was restricted to the immature B
cell stages at which both heavy and light chain genes are rear-
ranged and encode BCRs (Figures 3D and 3E) (Meffre et al.,
2000). We conclude that AID proteins appear to be confined to
a discrete population of B cells expressing BCRs that are
selected by central B cell tolerance.
Figure 2. Decreased AID Expression in Asymptomatic Healthy Individuals Carrying One Mutated AICDA Allele
(A) Quantitative real-time PCR shows decreased transcript of AICDAmRNA in EBV-transformed B cell lines from AICDA+/ asymptomatic healthy heterozygotes
(n = 6), AID-def. patients (n = 5) and healthy donors (HD) (n = 10). Transcripts were normalized to HPRT1.
(B) Immunoblot analysis of total protein lysates from EBV-transformedB cell lines from healthy donors (HD), asymptomatic healthy heterozygotes (AICDA+/), and
AID-def. patients. Immunoblotting against b-actin was used as loading control. Quantification is summarized in (C).
(D) Cytospin slides of sorted CD3+ T cells, CD19+IgD+CD38CXCR4B cells and CD19+IgDCD38+CXCR4+ GC B cells were stained for Igk/Igl and mouse anti-
AID or concentration matched isotype control.
(E) Cytospin slides of CD20+ B cells isolated from healthy donor (HD), AICDA+/, or AID-def. patients stimulated with CD40L+IL-2+IL-21 were stained for Igk+Igl
(green) and mouse anti-AID (red). AID expression is detected in GC but not in naive B or T cells and not in AID-deficient B cells stimulated with cytokines that
induce AID expression in AID competent B cells. Original magnification 40X, scale bar represents 10 mm. Data are representative of two independent experiments
for (B), (D), and (E).AID Proteins Are Expressed in RAG2+ Early Immature B
Cells
To exclude that AID+ cells were mature B cells, which also ex-
press BCRs and are present in CD19+ cells from adult BM
though not in fetal liver, we tested the expression by immunohis-
tochemistry of RAG2, which catalyzes V(D)J recombination in
lymphocyte precursors when combined with RAG1 (Schatz
and Swanson, 2011). Monoclonal rabbit anti-RAG2 antibodies
labeled fetal liver B cell precursors but did not stain naive or
GC B cells when these B cells were isolated and deposited on
cytospin slides or in human tonsil sections (Figures 4A and 4B).
Most fetal liver and adult BM B cells that expressed AID were
found to co-express RAG2, demonstrating that AID+ B cells
were true precursors likely undergoing Ig gene rearrangements
and not hypothetical recirculating GC B cells (Figures 4C and
4D). While RAG2 was detected in both the nucleus and the cyto-
plasm, AID expression in immature B cells appeared enriched in
the cytoplasm, a feature that is also observed in GC B cells (Fig-Iure 4) (Rada et al., 2002). Since RAG2 is rapidly degraded when
cells enter S phase, AID+ B cell precursors are likely in a resting
or G1 phase (Grawunder et al., 1995; Li et al., 1996). In addition,
the expression of RAG2 in AID+ immature B cells expressing
both Ig heavy and light chains, suggests that these B cells are
undergoing receptor editing, a mechanism involving secondary
recombination events that is important for central B cell toler-
ance (Goodnow, 1996; Nemazee, 2006; Radic and Weigert,
1995). Thus, AID proteins are expressed in a discrete population
of early immature B cells, which might produce self-reactive
BCRs and express RAG to keep recombining Ig genes in order
to tolerize these clones.
Most AID-Expressing Immature B Cells Are Undergoing
Apoptosis
We further characterized AID+ early immature B cells by com-
paring these cells to GC B cells that also express AID. We first
assessed whether BCL6, a transcription factor critical for GCmmunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc. 887
Figure 3. AID Is Expressed in Immature B
Cells
(A) Tonsil and fetal rib (115 day old) sections were
stained for AID (red) and IgM (green). Higher
magnification (right panel) reveals presence of
IgM+AID+ cells in fetal rib. Data are representative
of three independent fetal rib samples and one
tonsil sample. Scale bar (left to right) represents
50, 200, and 25 mm.
(B) Quantitative real-time PCR shows presence of
AICDAmRNA transcript in CD34CD19+ fetal liver
(FL) and fetal BM samples. Transcripts were
normalized to HPRT1.
(C) 0.1%–2.5% of sorted CD19+IgDCD38+
CXCR4+ GC B cells were spiked in peripheral
mature naive CD19+ B cells and AICDA mRNA
transcript was measured. A relative AICDA
expression of 0.05–0.06 in FL and fetal BM as
measured in B corresponds to 0.40%–0.55% of
CXCR4+ GC B cells.
(D, E) Cytospin slides of CD34CD19+ purified
fetal liver or adult bone marrow (BM) cells were
stained for IgM, Igk+Igl, or VpreB (green) and AID
(red) and quantified for co-staining. AID protein is
expressed in 0.9% ± 0.4% of total CD34CD19+
cells. Data are representative of three fetal liver
and one adult bone marrow sample(s). Error bars
represent mean ± SD. Original magnification 40X,
scale bar represents 10 mm.development and regulating AID expression, was expressed in
human B cell precursors (Basso and Dalla-Favera, 2012). Anti-
BCL6 monoclonal antibody stained many GC B cells but not
naive B cells as previously reported (Figure 5A and Figure S3A)
(Basso and Dalla-Favera, 2012). AID expression in CXCR4+ GC
B cells was found restricted to cells that co-expressed BCL6
(Figure S3A). We detected BCL6 expression in some B cell pre-
cursors from human fetal liver and adult BM (Figure 5B). Most of
these AID+ cells also co-expressed BCL6, suggesting that a
similar program potentially induced by BCRs recognizing (self-)
antigens might take place in some early immature and GC B
cells (Figure 5B). We then investigated the expression of anti-
apoptotic factors allowing B cell precursor andGCB cell survival
(Fang et al., 1996; Opferman et al., 2003; Smith et al., 1994; Vik-
strom et al., 2010). We could not analyze BCL2 or BCL-XL
expression because cell fixation procedures allowing AID detec-
tion inhibited the detection of these molecules using several
antibodies. However, we were able to detect MCL-1, an anti-
apoptotic factor required for both precursor and GC B cell
survival in many GC B cells from tonsil sections or cytospins
(Figure 5C and Figure S3B) (Opferman et al., 2003). In contrast,
we found that AID+ early immature B cells from fetal liver and
adult BM were devoid of MCL-1, suggesting that these B cell
precursors may not be protected from apoptosis (Figure 5D).
Indeed, they often expressed active caspase-3, characteristic888 Immunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc.of apoptotic cells, whereas only rare GC
B cells were stained for such marker (Fig-
ures 5E and 5F, and Figure S3C) (Porter
and Ja¨nicke, 1999). Hence, most AID+
early immature B cells that express
RAG2 and undergo receptor editing failto be rescued from cell death and are likely being deleted. Our
observation is in agreement with the dearth of GFP+ B cells ex-
iting the bone marrow of Aicda-cre x Rosa-floxed-GFP mice in
which GFP expression is turned on when AID expression is
induced (Crouch et al., 2007). Although it was initially postulated
that the lack of GFP+ B cells in this mouse model resulted from
the absence of AID expression during early B cell development,
our data suggest that AID might be induced in developing autor-
eactive B cells that eventually get eliminated.
Central B Cell Tolerance Requires B Cell Intrinsic AID
Expression
We proceeded to test the B cell intrinsic requirement of AID
expression to eliminate autoreactive immature B cells by devel-
oping a model for human central B cell tolerance in which
AID expression could be inhibited using specific shRNA. Human-
ized mice were produced by engrafting NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) immunodeficient mice with CD34+ he-
matopoietic stem cells (HSCs) isolated from human fetuses
(Shultz et al., 2005). Alternatively, HSCs were transduced over-
night with lentiviruses expressing either GFP-tagged AID spe-
cific shRNA or control shRNA before transfer into NSG mice
(Figure 6A) (Schickel et al., 2012). We characterized an AID
specific shRNA, AID shRNA3, that could inhibit 50%–70% of
AID expression that was detected either by quantitative PCRs
Figure 4. AID Is Co-expressed with RAG2 in
Early Immature B Cells
(A) Cytospin slides of sorted CD19+IgD+CD38
CXCR4 naive B cells, CD19+IgDCD38+CXCR4+
GC B cells and CD34CD19+ fetal liver B cell
precursors were stained for RAG2 or concentra-
tion matched isotype control (green) and AID
(red) and co-staining was quantified. Data are
representative of two independent experiments.
Original magnification 40X, scale bar represents
10 mm.
(B) Tonsil tissue sections stained for AID (red) and
RAG2 (green) showed no RAG2 staining. Data
are representative of one tonsil sample. Original
magnification 20X, scale bar represents 50 mm.
(C and D) Cytospin slides of CD34CD19+ purified
fetal liver or adult bone marrow cells were stained
for RAG2 (green) and AID (red) and co-staining was
quantified. Most AID+ B cells co-express RAG2.
Data are representative of three fetal liver and one
adult bone marrow sample(s). Error bars represent
mean ± SD. Original magnification 40X, scale bar
represents 10 mm.(Figure 6B) or by immunoblot using the human RAMOSB cell line
transduced with GFP-tagged AID shRNA3 (Figures 6C and 6D).
Subcloning of GFP+ RAMOS transduced with AID shRNA3
further showed that 48%–92% of AID expression could be in-
hibited using this strategy (Figure 6E). Since the loss of a single
AICDA allele, which reduces AID expression by about 50% re-
sults in central B cell selection defects (Figures 1 and 2), the
shRNA-induced decrease in AID expression might also interfere
with the removal of developing autoreactive B cells. Human
CD19+ B cells developed in NSG mice engrafted with HSCs
transduced or not with lentiviruses; 11.7%–52.5% of new
emigrant B cells expressed GFP indicative of shRNA expression,
revealing that HSCs transduced with lentiviruses retained
engraftment and B cell development abilities (Figure 6F). The
analysis of the reactivity of antibodies cloned from splenic
CD19+CD27CD10+IgMhiCD21lo new emigrant B cells from
NSG mice transplanted with HSCs isolated from four distinct fe-
tuses showed that the frequencies of polyreactive clones were
similar to those of new emigrant B cells isolated from the blood
of healthy donors, demonstrating that central B cell tolerance
is established normally in humanized mice (Figures 6G and 6H,
Figure S4A, and Table S4). The frequencies of new emigrant B
cells that produced HEp-2 reactive antibodies were lower in
NSG mice compared to healthy donors, a feature that might
reflect differences between fetal and adult HSCs (Figures 7A
and 7B and Figure S4B). Anti-nuclear reactivity in new emigrant
B cells was very rare and comparable between humanized mice
and healthy donors, further attesting of the proper counterselec-
tion of human autoreactive clones in mouse bones (Figure 7C).
Altogether, these data reveal that NSG humanized mice repre-
sent a good model for human central B cell tolerance.
In contrast, new emigrant B cells expressing AID shRNA con-
tained many autoreactive clones expressing polyreactive anti-
bodies (Figures 6G and 6H, Figure S4 and Table S5). The defec-
tive central B cell tolerance induced by AID shRNA was also
evidenced by the high proportion of HEp-2 reactive and anti-nu-Iclear GFP+ new emigrant B cells (Figure 7). Anti-nuclear staining
patterns of antibodies from new emigrant B cells that developed
with decreased AID expression were very diverse and included
chromatin and non-chromatin reactive clones (Figure 7D). While
a high proportion of GFP+ B cells expressing AID shRNA ex-
pressed autoreactive antibodies, GFP new emigrant B cells
that did not were properly selected in the same mouse (Figures
6G and 6H, Figure S4, and Table S5). In addition, lentiviral trans-
duction per se did not interfere with the counterselection of
BM autoreactive B cells because GFP+ new emigrant B cells ex-
pressing the control shRNA displayed normal proportions of pol-
yreactive, HEp-2 reactive, and antinuclear clones (Figures 6G
and 6H, Figure S4, Figure 7 and Table S5). These data therefore
demonstrate the B cell-intrinsic requirement of AID expression
for the BM removal of developing autoreactive B cells and the
establishment of human central B cell tolerance.
During early B cell development, DNA double-strand breaks
induced by RAG and potentially AID activate DNA damage
response controlled by gatekeeper p53, which induces cell-
cycle arrest or apoptosis (Green and Kroemer, 2009; Kruse
and Gu, 2009). To determine whether p53 blockade might
interfere with the negative selection of developing B cells, NSG
humanized mice engrafted with HSCs from different donors
were injected intraperitoneally (i.p.) daily for a week with pifi-
thrin-a (PFTa) p53 inhibitor (Figure S5A) (Komarov et al., 1999).
PFTa-treated NSG humanized mice showed elevated fre-
quencies of new emigrant B cells expressing polyreactive
and HEp-2 reactive antibodies, including ANAs that were
similar to those when AID expression was inhibited (Figures
S5B–S5D and Table S6). In addition, PFTa-treated NSG human-
ized mice displayed 5-fold-increased frequencies of AID-ex-
pressing B cell precursors in their BM compared to untreated
humanized mice, suggesting that p53 inhibition rescue AID-ex-
pressing B cell precursors from apoptosis and/or clearance (Fig-
ure S6). Hence, the inhibition by PFTa of p53 activation likely
induced by RAG- and AID-mediated DNA double-strand breaksmmunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc. 889
Figure 5. AID+ Cells Are Undergoing Apoptosis
Tonsil tissue section (A) or cytospin slides of CD34CD19+ purified fetal liver or adult bone marrow (BM) (B) were stained for BCL6 (green) and AID (red) and co-
staining was quantified. Most AID+ cells co-express BCL6. Tissue section of tonsil (C) or cytospin slides of CD34CD19+ purified fetal liver or adult BM (D) were
stained for MCL-1 (green) and AID (red), and co-staining was quantified. The vast majority of AID+ cells do not express anti-apoptotic MCL-1. Tissue section of
tonsil (E) or cytospin slides of CD34CD19+ purified fetal liver or adult BM (F) were stained for active caspase-3 (green) and AID (red) and co-staining was
quantified. AID and activated caspase-3 co-staining reveals that many AID+ cells fail to be rescued from cell death by apoptosis. Data are representative of three
fetal liver, one adult bone marrow, and one tonsil sample(s). Error bars represent mean ± SD; scale bar represents 50 mm (A, C, and E) and 10 mm (B, D, and F).
Please see also Figure S3.in developing autoreactive B cells prevents the counterselection
of these B cell precursors in the BM. Taken together, AID expres-
sion in autoreactive immature B cells might lead to their elimina-
tion in the bone marrow.
DISCUSSION
The identification of an impaired central B cell tolerance check-
point in AR-AID-deficient and AICDA+/ individuals who exhibit
no or reduced AID expression, respectively, emphasizes the
importance of AID in the removal of developing autoreactive B
cells. The absence of BM counterselection defects in patients890 Immunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc.with rare AD-AICDA mutation that abolishes CSR but preserves
enzymatic activity argues that DNA cytidine deamination is a key
feature to ensure central tolerance. In agreement with the previ-
ous detection of AID transcripts in B cell precursors, we identi-
fied AID protein expression in a discrete population of immature
B cells, suggesting that AID might be mediating its tolerogenic
function fromwithin developing B cells. In addition, the induction
of CSR in mouse pre-B cells in vitro and in vivo previously
demonstrated that AID enzyme could be induced in B cell pre-
cursors (Han et al., 2007; Mao et al., 2004; Rolink et al., 1996).
The inhibition of AID expression in developing B cells in human-
ized mice resulted in a failure to remove autoreactive clones,
Figure 6. Inhibition of AID Expression dur-
ing B Cell Development Interferes with the
Removal of Polyreactive Clones
(A) Schematic diagram depicting the generation
of humanized mice. CD34+ hematopoietic stem
cells (HSCs) were transduced with lentiviruses
allowing the expression of AID or control shRNA
before being injected in the liver of 3-day-
old recipient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
mice.
(B) Relative expression of AICDA in Ramos cells
transfected with control shRNA, or three different
shRNAs targeting human AICDA cDNA sequence.
Values are normalized to HPRT1. Data shows the
mean of three independent experiments.
(C) Transfection efficiency and sorting strategy for
Ramos cells transfected with GFP-tagged AID
shRNA3.
(D) AID protein expression in Ramos cells trans-
fected with control shRNA or AID shRNA3
after sorting GFPlo or GFPhi expressing cells.
Protein expression of b-actin is used for normali-
zation. Percentage of knockdown is indicated.
Data are representative of two independent
experiments.
(E) AID protein expression in subclones of Ramos
transfected cells with shRNA3. Protein expression
of b-actin is used for normalization. Percentage of
gene silencing is indicated. Data is representative
of two independent experiments
(F) Transduction efficiency and sorting strategy of
the GFP+ shRNA+ fractions in hCD45+hCD19+ B
cells.
(G) B cell intrinsic AID expression is required for
central B cell tolerance. Antibodies from new
emigrant B cells isolated from control humanized
mice and sorted GFP as well as GFP+ fractions
expressing AID shRNA or control shRNA were
tested by ELISA for reactivity against dsDNA, in-
sulin, and LPS. Polyreactive antibodies reacted
against all three antigens. Dotted lines showED38-
positive control. Horizontal lines show cutoff
OD405 for positive reactivity. For each mouse, the
frequency of polyreactive and non-polyreactive
clones is summarized in pie charts, with the
number of antibodies tested indicated in the
center. The frequencies of polyreactive new emigrant B cells in healthy donors and humanizedmice expressing or not the indicated shRNA are summarized in (H).
Each symbol represents an individual or mouse, and the horizontal bars show the average. Please see Figure S4.whereas B cells that could express AID in the same mice did
not express self-reactive antibodies, demonstrating the B cell
intrinsic requirement for AID expression in the establishment of
central tolerance. Hence, AID enzymatic activity is essential
not only for mediating CSR and SHM but also for the silencing
of BM developing autoreactive B cells.
How does AID expression induced in early immature B cells
mediate central B cell tolerance? Receptor editing, the major
mechanism to ensure central B cell tolerance, is mediated by
secondary recombination catalyzed by RAG enzymes and is
induced in immature B cells expressing autoreactive BCRs
(Goodnow, 1996; Meffre et al., 2000; Nemazee, 2006; Radic
and Weigert, 1995). The identification of RAG2 in AID+ immature
B cells therefore suggests that these B cells might express autor-
eactive BCRs and are undergoing secondary recombination to
edit such receptors. The binding of self-antigens including nu-Iclear antigens might therefore trigger autoreactive BCRs and
TLRs in immature B cells and induce AID expression (Han
et al., 2007; Meyers et al., 2011; Perez et al., 2010; Umiker
et al., 2014). The co-expression of BCL6, previously shown
to be required for the generation of a diverse Ig repertoire,
might also play an important role in the induction of AID
in autoreactive developing B cells (Basso and Dalla-Favera,
2012; Duy et al., 2010). In addition, BCL6 augments BCR
signaling and suppresses anti-apoptotic BCL2 expression
(Juszczynski et al., 2009; Saito et al., 2009). BCL6 might there-
fore favor the silencing of autoreactive immature B cell poten-
tially enhancing deletion associated with strong BCR signaling
(Meffre et al., 2000). In humans, early immature B cells, which
do not express surface BCRs and were identified in sorted BM
CD19+CD34CD27CD10+IgM ‘‘pre-B’’ cells, produce highly
self-reactive and anti-nuclear antibodies and might thereforemmunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc. 891
Figure 7. Central B Cell Tolerance Requires
B Cell Intrinsic AID Expression
(A) Antibodies from new emigrant B cells isolated
from control humanized mice and sorted GFP as
well as GFP+ fractions expressing AID shRNA or
control shRNA were tested by ELISA for reactivity
against HEp-2 cell lysate. Solid lines show binding
for each cloned recombinant antibody. Dotted
lines show ED38-positive control. Horizontal lines
show cutoff OD405 for positive reactivity. For each
mouse, the frequency of HEp-2 reactive and non
HEp-2 reactive B cells are summarized in pie
charts, with the number of antibodies tested
shown in the center. The frequencies of HEp-2
reactive (B) and anti-nuclear (C) new emigrant B
cells are compared between healthy donors and
humanized mice expressing or not the indicated
shRNA. Each symbol represents an individual or
mouse, and the horizontal bars show the average.
(D) Anti-nuclear antibodies expressed by new
emigrant B cells expressing AID shRNA show
various chromatin reactive and non-reactive nu-
clear reactivity. Original magnification,3 40. Scale
bar represents 10 mm. Please see Figure S4.contain clones in which AID is induced (Wardemann et al., 2003).
Becausemost AID+ immature B cells undergo apoptosis as illus-
trated by the identification of active caspase-3, AID expression
might therefore lead to cell death and the deletion of autoreactive
B cells that fail to silence self-reactive BCRs. If onemousemodel
reporting AID-expression failed to detect BM AID-expression
without infection (Crouch et al., 2007), another identified rare
BM immature B cells that have previously expressed AID, sug-
gesting that some cells might escape deletion potentially after
editing their BCRs (Qin et al., 2011). Because AID-deficient
B cells have been reported to be less sensitive to apoptosis, au-
toreactive immature B cells lacking AID might be resistant to
deletion and escape central B cell tolerance, especially since re-
ceptor editing has also been reported to be affected by the lack
of AID (Zaheen et al., 2009) (Kuraoka et al., 2011; Umiker et al.,
2014). Because apoptotic developing B cells are rapidly elimi-
nated by surrounding macrophages, it might explain why AID
is only detected in a discrete and transient population of imma-
ture B cells but might in fact account for the removal of many au-
toreactive clones, thereby ensuring central B cell tolerance. In
line with this hypothesis, p53 inhibition by PFTa abrogated
central B cell tolerance and increased the frequency of BM
AID-expressing B cells, suggesting that p53 blockade might
rescue developing autoreactive B cells from apoptosis (Komarov
et al., 1999). We propose that AID might induce DNA lesions that
activate p53 function, leading to the elimination of autoreactive
clones. The co-expression of RAG in AID+ early immature B cells
likely further increases the amount of DNA damage sustained by
these cells, as a result of receptor editing and potentially by
RAG-induced DNA double-strand breaks at AID-deaminated
methyl-CpG motifs (Tsai et al., 2008). Importantly, our identifica-
tion of a developmental stage at which both AID and RAG are ex-892 Immunity 43, 884–895, November 17, 2015 ª2015 Elsevier Inc.pressed simultaneously provides a rationale for translocation
events occurring in pre-B ALL cases that were predicted to be
mediated by concerted RAG and AID activity (Tsai et al., 2008).
The requirement of both AID and RAG expression for leukemia
to emerge from B cell precursors has now been demonstrated
in mice (Swaminathan et al., 2015). Hence, leukemic transforma-
tion in B cell precursors might represent a failure of central B cell
tolerance.
EXPERIMENTAL PROCEDURES
Patients and Healthy Donor Controls
We obtained peripheral blood or frozen PBMC from 16 AR-AID-def. patients,
with homozygote or compound heterozygote autosomal recessive AICDAmu-
tations of which nine were described previously (Meyers et al., 2011). In addi-
tion, we collected samples from 12 healthy donors related to these patients
carrying one autosomal recessivemutatedAICDA allele, 4 AD-AICDA patients,
and 3 UNG-deficient patients, one of which was positive for the PTPN22 risk
allele and therefore excluded from our analysis because this polymorphism
correlates defective early B cell tolerance checkpoints in healthy donors (Me-
nard et al., 2011). All patients’ information is included in Table S1. Age-
matched healthy donors were previously reported, except for healthy donor
HD30 (45-year-old Caucasian female) (Kinnunen et al., 2013; Menard et al.,
2014; Romberg et al., 2013). Fetal liver was obtained from six different fetuses
aged day 100–115 and bone marrow samples from donors. All samples were
collected in accordance with institutional review board-reviewed protocols
Cell Staining and Sorting
Peripheral B cells were purified from the blood of patients and control donors
by positive selection using CD20-magnetic beads (Miltenyi). Enriched B cells
were stained with following antibodies: anti-CD19-Pacific Blue, anti-CD27-
PercP-Cy5.5, anti-CD10-PE-Cy7, anti-IgM-FITC, anti-CD21-APC, and anti-
IgG-PE (all from BioLegend). Single CD19+CD21loCD10+IgMhiCD27 new
emigrant and CD19+CD21+CD10IgM+CD27 mature naive B cells from pa-
tients and healthy donors were sorted on a FACSAria flow cytometer (Becton
Dickinson) into 96-well PCR plates. For phenotyping, enriched B cells were
stained with anti-CD19-Pacific Blue, anti-CD27-PercP-Cy5.5, anti-CD10-PE-
Cy7, anti-IgM-FITC (all from BioLegend), anti-IgG-APC, and anti-IgA-PE
(BD). Following cell suspensions were isolated, counted and deposited
on poly-L-lysine-coated glass slides in a cytospin centrifuge and stored
at 80C until usage. Tonsil was smashed on a 40 mm strainer and enriched
using CD19 magnetic beads (Miltenyi). Tonsil cells were sorted with
following mixes: anti-CD3-FITC (ebioscience), anti-CD38-PE (BD), anti-IgD-
PercP-Cy5.5, anti-CD10-PE-Cy7, anti-CXCR4-APC, anti-CD19-Pacific Blue
(all from BioLegend). For AID detection in peripheral B cells, CD20+ enriched
cells were stimulated with 100 ng/nl of human recombinant trimeric
CD40L (Enzo Life Sciences), 50 U/mL of interleukin-2 (IL-2) (Peprotech), and
50 ng/mL of IL-21 (R&D systems) for 2 days. After 48 hr of culture, the medium
was replaced by fresh RPMI containing 50 U/mL of IL-2 and 50 ng/mL of IL-21
without CD40L and the cells were cultured for another 48 hr. Fetal liver was
smashed on a 40 mm strainer, depleted of CD34+ cells using magnetic beads
(Miltenyi), and enriched for CD19 using magnetic beads (Miltenyi). Adult hu-
man bonemarrow aspirate was depleted of CD34+ cells usingmagnetic beads
(Miltenyi) and enriched for CD19 using magnetic beads (Miltenyi)
cDNA, RT-PCR, Antibody Production, and Purification
RNA from single cells was reverse-transcribed in the original 96 well plate in
12.5 ml reactions containing 100 U of Superscript II RT (GIBCO BRL) for
45 min at 42C. RT-PCR reactions, primer sequences, cloning strategy,
expression vectors, antibody expression, and purification were as described
(Wardemann et al., 2003).
ELISAs and IFAs
Antibody concentrations and reactivity were measured as described (Warde-
mann et al., 2003). Highly polyreactive ED38 was used as positive control in
HEp-2-reactivity and polyreactivity ELISAs. Antibodies were considered poly-
reactive when they recognized all three analyzed antigens, which included
double-stranded DNA (dsDNA), insulin, and lipopolysaccharide (LPS). For
indirect immunofluorescence assays, HEp-2 cell coated slides (Bion Enter-
prises, LTD) were incubated in a moist chamber at room temperature with
purified recombinant antibodies at 50-100 mg/mL and detected with FITC-con-
jugated goat anti-human IgG.
Tissue Sections, Cytospins and Immunofluorescence
Tonsil and fetal ribs were immediately embedded in Tissue Tek Optimum Cut-
ting Temperature (OCT) (Sakura) and immediately frozen using a mixture of
isobuthanol and dry ice, and stored at 80C. 7 mm cryostat sections of fetal
rib were transferred to CJ1X adhesive coated slide using the Cryojane Tape
Transfer System (Instrumedics) according to the manufacturer’s protocol.
Prior to staining, all slides were fixed in 4% paraformaldehyde and permeabi-
lized in 5% donkey serum, 0.5% BSA, and 0.05% Tween-20. The following
primary antibodies were used for stainings: mouse anti-AID (Invitrogen, clone
ZA-001), rat anti-AID (cell signaling, clone EK2-5G9), mouse anti-IgM (Santa
Cruz, clone SA-DA4), rabbit anti-Igk (Dako, polyclonal), rabbit anti-l (Dako,
polyclonal), mouse anti-VpreB (BioLegend, polyclonal), rabbit anti-RAG2 (gift
from D. Schatz), mouse anti-BCL6 (BD bioscience, clone K112-91), rabbit
anti-MCL-1 (Abcam, polyclonal), mouse anti-BCL2 (Abcam, clone 4D7), rabbit
anti-BCL-XL (Abcam, polyclonal), and rabbit anti-active caspase 3 (BD
Bioscience, clone C92-605). Primary antibodies were revealed with donkey
anti-mouse AlexaFluor 647 (Invitrogen), goat anti-rat PE (Santa Cruz Biotech-
nology) followed by donkey anti-goat PE (Jackson ImmunoResearch), and
donkey anti-rabbit AlexaFluor 488. Nuclei were counterstained with DAPI (In-
vitrogen) and 1,000 nuclei per cytospin sample were analyzed. Double-blinded
detection of AID+ cells was performed for BM CD19+ cells of NSG control and
PFTa-treated mice.
Immunoblot and QPCR
For detection of AID Ramos cell lines, RNAwas extracted using the Absolutely
RNA Microprep Kit (Agilent Technilogies) and 150 ng RNA was reverse tran-
scribed using random hexamers (Applied Biosystems) and SuperScript III
Reverse Transcriptase kit (Invitrogen). For mRNA gene expression assays,
probes were purchased from Applied Biosystems: HPRT1: Hs02800695_m1,
AICDA: Hs00757808_m1. Reactions were run on a 7500 Real-Time PCR sys-Item (Applied Biosystems) in duplicate. Values are represented as the differ-
ence in Ct values normalized toHPRT1 for each sample. For AID protein detec-
tion, cells were lysed in lysis buffer (50 mM Tris, 1% NP-40, 2 mM EDTA)
including protease inhibitor (Roche). Total cell lysates were separated by
SDS page, transferred to PDVF membranes, probed with mouse anti-AID (In-
vitrogen) and anti-mouse HRP (Cell Signaling) and detected by chemilumines-
cence (Amersham ECL Prime Western Blotting detection Reagent) using a
GBox documentation system (Syngene). For quantification, blots were strip-
ped with stripping buffer (Pierce) and reprobed with a mouse anti- b-actin anti-
body (Sigma-Aldrich).
AID Silencing and CD34+ HSCs Transduction
The pTRIP-Ubi-GFP lentiviral vector has been used for short hairpin RNA
(shRNA) delivery. For the construction of pTRIP-shAID, a DNA fragment con-
taining the H1 promoter and a AID shRNA sequence was generated by double
digestion of pSUPER-shAID plasmid (made by inserting a shRNA targeting
human AID cDNA sequence shRNA1: 50-CTTTGGTTATCTTCGCAATAA-30,
shRNA2: 50-ACCACGAAAGAACTTTCAAAG-30 or shRNA3: 50-AAGCATGGT
GAGAGGATCAAA-30 or control shRNA into pSUPER plasmid) and was subcl-
oned within the 30 long terminal repeat of pTRIP-Ubi-GFP vector. Lentiviral
particles were produced by transient transfection of 293T cells, as previously
described (Schickel et al., 2012). Viruses were then used to transduce CD34+
HSCs in the presence of polybrene (Sigma).
Human Progenitor Cell Isolation and Injection in NSG Mice
Human CD34+ cells were purified from fetal liver samples by density gradient
centrifugation followed by positive immunomagnetic selection with anti-hu-
man CD34 microbeads (Miltenyi). Newborn NSG mice (within first 3 days of
life) were sublethally irradiated (X-ray irradiation with X-RAD 320 irradiator at
180 cGy) and 100,000–150,000 CD34+ cells in 20 ml of PBS were injected
into the liver with a 22-gauge needle (Hamilton Company). Mice were used
for experiments 10–12 weeks after transplantation. NSG mice treated with
Pifithrin-a (PFTa, Sigma) were injected daily i.p. with 50 mg PFTa for a week.
All animals were treated and experiments were conducted in accordance
with the Yale institutional reviewed guidelines on treatment of experimental
animals.
Statistics
Statistical analysis was performed using GraphPad Prism (version 5.0; Graph-
Pad). Data are reported as mean ± SD. Differences between groups of
research subjects were analyzed for statistical significance with unpaired
two-tailed Student’s t tests. A p value of% 0.05 was considered significant.
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